Amrutanjan Health Care's record is mixed: seven years of clean audit opinions sit alongside one qualified opinion, a crystallised lease dispute, and recurring auditor flags on revenue timing and audit trails. The balance sheet is debt-free with ₹222.88 crore in cash and investments, but cash conversion has weakened and capital is being deployed into a ₹150 crore greenfield plant.
Key findings
- Lease dispute from FY2005-06 became a ₹9.75 crore payout and ₹7.71 crore provision
Major- The Company paid lease arrears of ₹9,74,67,151 to Arulmigu Kapaleeswarar Temple on August 1, 2026, after the Madras High Court dismissed its writ petition on September 25, 2025 and the Division Bench dismissed its appeal on March 16, 2026. The dispute originated from a demand notice issued in FY2005-06 with retrospective effect from November 2001. The provision for disputed liabilities rose from ₹1.10 crore to ₹8.81 crore during FY2025-26, with ₹7.71 crore provided in the year. - A whistle-blower complaint produced the only qualified audit opinion in seven years
Major- B S R & Co. LLP qualified the FY2022-23 opinion after a December 2022 complaint led to a forensic audit reporting ₹8.65 lakh in potential kickbacks to employees from vendors. The auditor also flagged a material weakness in vendor onboarding. Audit-trail exceptions have recurred: for FY2025-26, backups were not kept on servers in India daily, and the auditor could not comment on the audit trail for payroll and one invoicing system. - Revenue recognition is a Key Audit Matter every year, with contract liabilities swinging from ₹1.56 crore to ₹123.44 crore
Major- The auditor flagged revenue recognition as a Key Audit Matter in every annual report from FY2020 through FY2026, citing risk of revenue recognised in the wrong period. Contract liabilities recognised as revenue were ₹123.44 crore in FY2026 versus ₹1.56 crore in FY2022. The company has stated since FY2020 that no single customer provides 10% or more of revenue. - Regulator actions are limited, but the company's own forensic audits found ₹16.31 lakh in irregularities
Major- An MCA inspection was compounded, and a Legal Metrology notice was settled by paying fees. Secretarial audits flagged UPSI events not recorded in the Structured Digital Database and a 3-day committee constitution lapse. The whistle-blower forensic audit found ₹8.65 lakh in kickbacks and a further ₹7.66 lakh in contract labour irregularities. - Promoter control is stable and unpledged, but ESOP schemes have been repeatedly withdrawn and re-issued
Minor- Promoter shareholding is 46.52%, with zero pledge. ESOP Phase 2 was withdrawn on 17 April 2026 for missed targets, and a revised scheme was approved on 7 May 2026. The cancellation cost ₹2.69 crore, and 64,585 options lapsed in FY2021-22 and 6,592 in FY2023-24 for unmet vesting conditions. Employee remuneration particulars have been excluded from circulated annual reports since FY2020-21. - Cash generation has weakened while capital shifts to a greenfield plant
Minor- Cumulative CFO of ₹74 crore covered only 0.60x of cumulative EBITDA of ₹125 crore over ten years. CWIP rose from 16.2 crore to 105.48 crore in FY2025-26, with 89.28 crore added and no capitalisations. The sanitary napkin plant at Seetharampur involved a ₹150 crore investment per the Annual Report, while a credit rating press release states the plant cost ₹130 crore funded by internal accruals. Cash and investments stood at ₹222.88 crore as at March 31, 2026. - Accounting-policy choices have repeatedly shaped reported profit
Minor- Exceptional items of ₹1.25 crore for Labour Code impact flowed through the P&L in FY2025-26. The withdrawn ESOP scheme cost ₹2.69 crore. A tax-rate election under Section 115BBA reduced the corporate rate from 29.12% to 25.17% effective April 1, 2019, decreasing deferred tax assets by ₹58.30 lakh as at March 31, 2020.
What to watch
- GST appeal. Outcome of the appeal against the October 18, 2025 order demanding ₹1,17,66,455 plus interest and penalty.
- Sanitary napkin plant. Capitalisation of the 105.48 crore CWIP balance as at March 31, 2026.
- Revised ESOP 2. Whether vesting conditions are met under the scheme approved 7 May 2026, after the prior withdrawal.
- Contract labour investigation. Completion of the probe into contract/casual labour expenses, pending as of the FY2022-23 audit report dated May 30, 2023.
- EPF contingent liability. Resolution of the unquantified "Basic Wages" liability from the Supreme Court judgment dated February 28, 2019.
Bottom line: This is a debt-free, dividend-paying company with stable promoter control and no going-concern threat. The risk is operational and procedural: a crystallised legal dispute, recurring audit-trail gaps, and revenue recognition that auditors have flagged every year. Watch whether the GST appeals and the plant capitalisation resolve cleanly, and whether the revised ESOP scheme avoids another withdrawal.